Drugs / iC9/CAR.19/IL15-Transduced CB-NK Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03056339 | Jun 2017 → Mar 2023 | B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iC9/CAR.19/IL15-Transduced CB-NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03056339 ↗ |
| Modality | Cell therapy | “cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15)” PMID 38238616 ↗ Jan 2024 |
| Route | Intravenous | “Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.” NCT03056339 ↗ |
| Target | CD19 | “expressing anti-CD19 chimeric antigen receptor” PMID 38238616 ↗ Jan 2024 |